In-Depth Analysis of Synthetic Cannabinoids in France
Recent Discoveries and Health Concerns
In a context where innovation and vigilance in matters of substances modifying the state of consciousness are taking on increasing importance, the discussions during the last meeting of the Committee dedicated to Psychotropic Drugs, Narcotics and Addictions, orchestrated by the National Security Agency of Medicine ( ANSM ), have highlighted crucial points. Their discussions, now accessible to the public, focused on a series of synthetic cannabinoids currently marketed in France, notably H2CBD, H4CBD , THCP and HHCPO .
Attention to Potential Risks
These substances, identified in addictovigilance reports, have been associated with critical incidents, sometimes requiring hospital intervention due to negative experiences or other intense side effects, like those caused by H4CBD confectionery.
The Committee highlighted several alarming points:
- A theoretical danger associated with the generation of ketenes during the consumption of certain acetic esters (HHCO, HHCPO, THCO) by vaporization, revealing a problem already highlighted previously.
- For newly discovered cannabinoids, health concerns are comparable, if not greater, to those related to THC-containing products.
- Products including these substances are not always clearly identified, either on the packaging or to consumers.
The ANSM moderator recalled the main objective of classifying substances as narcotics, aiming above all to safeguard public health by protecting individuals from the well-identified deleterious effects of these new compounds.
Committee Recommendations
After in-depth analysis and advocacy from certain members, the committee supported the proposal to include the following cannabinoids on the list of narcotics:
- HHCPO = HHCP acetate = hexahydrocannabiphorol-O
- THCP = tetrahydrocannabiphorol
- H4-CBD (CBD derivative)
- H2-CBD (CBD derivative)
- THCA
Additionally, the committee expressed its intention to examine the possibility of also classifying cannabinol (CBN).
Decision Process and Implications
The conclusions of the committees are subject to evaluation by the ANSM, which will ultimately decide whether these molecules will be classified as narcotics, thus prohibiting their production, marketing, and consumption in France.
Note, in June 2023, the ANSM had already classified HHC, HHCO, and HHCP among narcotics. The recently mentioned synthetic cannabinoids had emerged on the market in an attempt to replace HHC, illustrating rapid replacement dynamics in the psychoactive substance landscape.
Conclusion
This regulatory update highlights the importance of constant monitoring and rigorous evaluation of psychoactive substances, synthetic or not, circulating on the market. It also recalls the responsibility of health authorities and consumers in preventing risks linked to their use. In an ever-changing landscape, commitment to public health remains paramount, guiding regulatory decisions and education initiatives to ensure the safety of all.